32
MECOR Turkey 2011

MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011

Page 2: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

Merhaba Istanbul!

Page 3: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Hosts

Arzu Yorgancıoğlu, MD

&

Oya Itil, MD

Turkish Thoracic Society

Page 4: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Director

A. Sonia Buist, MDOregon Health Sciences University

Director, ATS MECOR Program

Page 5: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Introductions

Page 6: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 1

Page 7: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 1

Page 8: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 1

Page 9: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 1

Page 10: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 1

Page 11: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 1

Page 12: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 2

Page 13: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 2

Page 14: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 2

Page 15: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 3

Page 16: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 3

Page 17: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 3

Page 18: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Students—Level 3

Page 19: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011Our Faculty

Page 20: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey Hard at WorkOur “conversations” in classrooms & hallways

Page 21: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey Hard at WorkOur “conversations” in classrooms & hallways

Page 22: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey Hard at WorkSmall Groups

Page 23: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey Hard at WorkSmall Groups

Page 24: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey What is the Question– Level 1

What is the prevalence and risk factors for smoking among medical students in Turkey?Do Turkish pulmonologists and pulmonary residents have the relevant up-to-date knowledge on COPD and adhere to the national COPD guidelines for the management of COPD?Does the Turkish Thoracic Society patient group education program improve asthma control in the asthma tertiary clinical setting?Are there any factors affecting the treatment outcomes of short course chemotherapy of pulmonary Tuberculosis in Istanbul?

Page 25: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey What is the Question– Level 2

Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006 and 2007-2010 time period?

Is spirometry screening useful for detecting undiagnosed COPD?

Are pulmonologists, who are current smokers, less likely toprovide smoking cessation counseling to their patients compared to non-current smokers?

Does a chemotherapy protocol which includes bevacizaumab decrease pulmonary arterial pressure?

Is actively supported smoking cessation associated with increased proportıon of smoking cessation among adult smokers?

Page 26: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey What is the Question– Level 3

What is the association between interlukin-17 response and tuberculosis status in children?Is the ACT asthma control test related with the asthma quality of life questionnaire?Does the PCT response change with age?What is the effect of positive airway pressure treatment on urine micro album levels?What is the comparative mortality in the ICU at one year post discharge between elderly patients and middle age patients admitted to the ICU?

Page 27: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey What is the Question– Level 3

What are the sociodemographic and clinical characteristics of pneumonia cases from an occupational disease hospital in Turkey?What is the attitude toward the 2009 smoking ban in Çorum, Turkey among healthcare workers who smoke?What is the seasonal relationship of blood lymphocyte apoptosis with bronchial hyperressponsiveness in seasonal allergic rhinitis?Copeptin and c-reactive protein, brain natriuretic peptide levels in the course of COPD exacerbation, a descriptive study

Page 28: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR TurkeyOur Celebration

Page 29: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR TurkeyOur Celebration

Page 30: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

MECOR Turkey 2011

Page 31: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

Acknowledgements

This course has been developed and implemented by the American Thoracic Society (ATS)

MECOR Turkey 2011 is supported financially and in kind by:

American Thoracic Society

Turkish Thoracic Society

The American Thoracic Society acknowledges and thanks

Drs. Arzu Yorgancıoğlu and Oya Itil and their colleagues who assisted in the organization of MECOR Turkey 2011.

Page 32: MECOR Turkey 2011 Slideshow.pptMECOR Turkey What is the Question– Level 2 Has the mortality rate of adult cancer patients admitted to the ICU demonstrated difference between 2002-2006

Gelecek yıl görüşmek üzere!

“Improving global lung health through development oflocal, country and regional lung disease research capacity”